查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1497651

生技藥品市場：按來源、產品、適應症和最終用戶分類 - 2024-2030 年全球預測

Biologics Market by Source (Mammalian, Microbial), Product (Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins), Indication, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年生技藥品市場規模為4,057.6億美元，預估2024年將達4,305.9億美元，2030年將達6,263.4億美元，複合年成長率為6.39%。

生技藥品是生物醫學領域不可或缺的一部分，該領域專注於開發、製造和銷售源自生物來源的生物治療藥物，以解決各種健康狀況。疫苗、基因治療和單株抗體等產品對於治療癌症、自體免疫疾病和遺傳疾病等嚴重疾病至關重要。這些治療對於醫學機構和需要創新治療的患者至關重要。可使用生技藥品治療的慢性疾病盛行率的上升正在推動生技藥品市場的成長。醫療基礎設施投資的增加和醫療成本的上升正在擴大先進生物製藥治療的獲取範圍，並為市場成長提供了跳板。高製造成本、生物相似藥日益激烈的競爭以及分銷所需的物流（尤其是低溫運輸要求）正在阻礙市場成長。人們越來越傾向於個人化醫療，即根據個人的基因組成提供量身定做的治療方法，預計將為市場成長創造機會。開拓生物技術公司和學術機構之間的研發合作夥伴關係，以加強與生技藥品相關的創新，預計將擴大市場範圍。

主要市場統計
基準年[2023] 4057.6億美元
預測年份 [2024] 4305.9億美元
預測年份 [2030] 6263.4億美元
複合年成長率（%） 6.39%

區域洞察

美洲因其強大的研究框架、大量投資和鼓勵創新的健全專利法而成為生技藥品市場的重要地區。此外，美國擁有成熟的生技藥品市場，並得到支持生物技術進步的醫療保健政策的支持。最近的進展包括 FDA 加速核准罕見疾病的生物治療方法，這表明政府的大力支持。美洲的主要企業不斷進行併購，推動該地區的成長和創新。歐盟 (EU) 對生技藥品有嚴格的監管標準，以確保治療的高度安全性和有效性。歐盟消費者重視永續且符合道德開發的產品，影響公司採用更環保的技術和實踐。歐洲藥品管理局（EMA）積極協調成員國，簡化生技藥品的核准流程，幫助新治療方法快速進入市場。中東和非洲地區充滿活力，海灣國家在醫療基礎設施和生技藥品方面進行了大量投資。消費者對生物治療的認知與接受程度不斷提高。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在生技藥品市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對生技藥品市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該領域競爭性質的寶貴見解，包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在生技藥品市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地慢性病盛行率正在上升
      • 對微創手術的需求和偏好日益成長
    • 抑制因素
      • 與生技藥品相關的治療成本上升
    • 機會
      • 生物材料的持續進步改善慢性病的治療
      • 擴大生技藥品相關生產設施
    • 任務
      • 生技藥品複雜製造的可用性
  • 市場區隔分析
    • 資料來源：哺乳動物細胞更適合產生更大、更複雜的蛋白質
    • 適應症：由 COVID-19 大流行和癌症研究進展推動的腫瘤學和感染疾病的持續創新
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章生技藥品市場：依來源分類

  • 哺乳動物的
  • 微生物

第7章生技藥品市場：依產品

  • 反義和RNAi療法
  • 單株抗體
  • 重組激素或蛋白質
  • 疫苗

第8章生技藥品市場的適應症

  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 感染疾病
  • 腫瘤學

第9章生技藥品市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第10章美洲生技藥品市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太生物生技藥品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的生技藥品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准首個托珠單抗生物相似藥 TOFIDENCE，擴大自體免疫疾病治療的可近性
    • 禮來公司擴大對愛爾蘭生技藥品製造工廠的投資
    • 山德士宣布對斯洛維尼亞新工廠進行重大投資
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4302AC72200D

[180 Pages Report] The Biologics Market size was estimated at USD 405.76 billion in 2023 and expected to reach USD 430.59 billion in 2024, at a CAGR 6.39% to reach USD 626.34 billion by 2030.

Biologics are integral to the biomedical sector, focusing on developing, manufacturing, and distributing biological treatments derived from living organisms to combat various health conditions. Products, including vaccines, gene therapies, and monoclonal antibodies, are pivotal in treating serious ailments such as cancer, autoimmune disorders, and genetic diseases. These treatments are crucial in healthcare facilities and also for patients in need of innovative therapies. The rising prevalence of chronic diseases that can be treated with biologics is driving the growth of the biologics market. Increasing investments in healthcare infrastructure and an increase in healthcare spending are widening the accessibility of advanced biologic treatments, creating a platform for market growth. High manufacturing costs, rising competition from biosimilars, and demanding logistics for distribution, particularly cold chain requirements hampers the market growth. A rising inclination toward personalized medicine that provides tailored therapies based on individual genetic makeup is expected to create opportunities for market growth. Growing partnerships in research and development between biotech companies and academic entities to enhance innovation associated with biologics are anticipated to expand the market scope.

KEY MARKET STATISTICS
Base Year [2023] USD 405.76 billion
Estimated Year [2024] USD 430.59 billion
Forecast Year [2030] USD 626.34 billion
CAGR (%) 6.39%

Regional Insights

The Americas represents a significant region in the biologics market, driven by strong research frameworks, substantial investments, and robust patent laws that encourage innovation. Additionally, America has a well-established biologics market supported by healthcare policies that favor biotechnological advancements. Recent trends include the FDA's accelerated approval of biological treatments for rare diseases, showcasing a significant government endorsement. Key players in the Americas are consistently engaging in mergers and acquisitions, bolstering growth and innovation in this region. The European Union exhibits stringent regulatory standards for biologics, ensuring high safety and efficacy of treatments. Consumers in the EU focus on sustainable and ethically developed products, influencing companies to adopt greener technologies and practices. The European Medicines Agency (EMA) actively coordinates across member states to streamline the approval processes for biologics, fueling rapid market entry of new therapies. The Middle East and Africa region presents a dynamic landscape, with Gulf countries investing heavily in healthcare infrastructure and the biologics sector. There is a growing awareness and acceptance of biological treatments among consumers.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Biologics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of chronic diseases worldwide
      • Growing need and preference for minimally invasive procedures
    • Market Restraints
      • High cost of treatment associated with biologics
    • Market Opportunities
      • Ongoing advancements in biomaterials improving the treatment of chronic disorders
      • Rising expansion of manufacturing facilities associated with biologics
    • Market Challenges
      • Availability of complex manufacturing of biologics
  • Market Segmentation Analysis
    • Source: Mammalian cells are preferable for producing larger and more complex proteins
    • Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biologics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biologics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases

Biogen Inc. announced that TOFIDENCE (tocilizumab-bavi), a biosimilar to the monoclonal antibody ACTEMRA, has received U.S. FDA approval for intravenous use in treating moderately to severely active rheumatoid arthritis, as well as polyarticular and systemic juvenile idiopathic arthritis. This marks the first tocilizumab biosimilar cleared in the United States, potentially offering significant cost savings and wider therapy accessibility. The approval is pivotal, considering the annual 10%-25% increase in spending on autoimmune treatments over the last decade. [Published On: 2023-09-29]

Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility

Eli Lilly invested in its biologics production facility, which is currently under construction in Raheen, Limerick County, Ireland. Eli Lilly injected an additional USD 500 million into the site, elevating its total expenditure to approximately 927 million USD 1 billion. [Published On: 2023-03-26]

Sandoz Announces Major Investment in New Biologics Facility in Slovenia

Sandoz invested over USD 400 million to construct a new biologics production facility in Lendava, Slovenia. This strategic development is aimed at bolstering the company's biosimilar portfolio. The construction underscores Sandoz's commitment to expanding its global presence while significantly contributing to local economic growth. [Published On: 2023-03-10]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biologics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Source
    • Mammalian
    • Microbial
  • Product
    • Antisense & RNAi Therapeutics
    • Monoclonal Antibodies
    • Recombinant Hormones or Proteins
    • Vaccines
  • Indication
    • Cardiovascular Disorders
    • Hematological Disorders
    • Immunological Disorders
    • Infectious Diseases
    • Oncology
  • End-user
    • Ambulatory Surgical Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need and preference for minimally invasive procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in biomaterials improving the treatment of chronic disorders
      • 5.1.3.2. Rising expansion of manufacturing facilities associated with biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of complex manufacturing of biologics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Mammalian cells are preferable for producing larger and more complex proteins
    • 5.2.2. Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Biologics Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Microbial

7. Biologics Market, by Product

  • 7.1. Introduction
  • 7.2. Antisense & RNAi Therapeutics
  • 7.3. Monoclonal Antibodies
  • 7.4. Recombinant Hormones or Proteins
  • 7.5. Vaccines

8. Biologics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Infectious Diseases
  • 8.6. Oncology

9. Biologics Market, by End-user

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Biologics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biologics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
    • 13.3.2. Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
    • 13.3.3. Sandoz Announces Major Investment in New Biologics Facility in Slovenia
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BIOLOGICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY MAMMALIAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY MICROBIAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY ANTISENSE & RNAI THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY ANTISENSE & RNAI THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES OR PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES OR PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. TURKEY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 360. TURKEY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 370. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 372. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 373. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 374. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 375. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 376. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 377. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 378. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023